Market News (Page 5) - TendieTensor

Market News Page 5 of 235 • 5,859 articles

Paychex Is Out of Favor—And That’s the Opportunity

Investing.com • Thomas Hughes

Paychex Is Out of Favor—And That’s the Opportunity

12/25/2025 07:44 AM • Paychex (PAYX) has declined to 52-week lows amid growth concerns and analyst downgrades, but the company maintains strong fundamentals with 17% revenue growth, healthy labor market demand, and a 3.8% dividend yield. The stock trades at 21x earnings—a discount to its historical 28x average—presenting a potential value opportunity for income investors. AI-driven product rollouts and improving market sentiment could serve as catalysts for a rebound, with analysts targeting around $110 as support and potential 25% upside.

GOOGL - Mentioned in context of YouTube TV dispute with Disney, no direct performance assessment
PAYX - Despite recent stock decline and analyst downgrades, the company demonstrates strong fundamentals including 17% revenue growth, raised FY2026 earnings outlook, healthy labor market demand, reliable 3.8% dividend yield with annual increases, and upcoming AI product catalysts. The stock is trading at a significant discount to historical valuations (21x vs. 28x average), presenting deep value opportunity with 25-100% upside potential over various timeframes.

#payroll services #dividend yield #value investing #AI products #labor market #institutional flows #insider selling #technical support #earnings growth

2 Growth Stocks Wall Street Might Be Sleeping On, but I'm Not

The Motley Fool • Anders Bylund

2 Growth Stocks Wall Street Might Be Sleeping On, but I'm Not

12/25/2025 07:31 AM • The article highlights Dutch Bros and Duolingo as undervalued growth stocks that Wall Street is overlooking. Dutch Bros has achieved 243% trailing revenue growth since its 2021 IPO with rapid expansion to 1,081 locations across 24 states, while trading down 26% from highs with a reasonable PEG ratio of 1.8. Duolingo posted 41% year-over-year revenue growth and 51% higher free cash flow in its latest quarter, though the stock is down 66% from record highs, now trading at attractive valuation multiples of 23.5x trailing earnings and 24x free cash flow.

CMCSA - Mentioned for opening Epic Universe theme park, potentially competing with Disney's theme park business
BROS - Company demonstrates exceptional 243% trailing revenue growth (36% CAGR) since IPO, rapid store expansion from 503 to 1,081 locations, efficient drive-thru business model with low maintenance costs, and reasonable PEG ratio of 1.8 despite rich P/E multiples. Stock down 26% from highs presents attractive entry point.

#growth stocks #undervalued #revenue growth #expansion #valuation multiples #subscription model #cash flow

Why 2026 Will Be the Year of the Tesla Robotaxi

The Motley Fool • Lee Samaha

Why 2026 Will Be the Year of the Tesla Robotaxi

12/25/2025 05:40 AM • Tesla plans to begin Cybercab production in April 2026 and aims to launch its robotaxi service, which could significantly impact the company's valuation. However, the company still needs critical regulatory approvals for unsupervised autonomous vehicle operation. While the robotaxi potential is substantial, investors should be cautious about production timelines outpacing regulatory clearance.

NFLX - Mentioned as a streaming competitor, but no specific performance details provided
TSLA - Tesla is making tangible progress on robotaxi development with planned Cybercab production starting in April 2026. The robotaxi service has massive revenue potential, with analyst projections suggesting 88% of enterprise value could derive from robotaxis by 2029. The company has 6.9 billion miles of FSD safety data demonstrating superior performance compared to human drivers.

#Tesla robotaxi #Cybercab production #autonomous vehicles #regulatory approval #unsupervised FSD #2026 rollout #Tesla Semi #Optimus robot

From BDCs to CEFs: Here’s How to Get 8% Dividends in 2026

Investing.com • Michael Foster

From BDCs to CEFs: Here’s How to Get 8% Dividends in 2026

12/25/2025 05:38 AM • The article explores Business Development Companies (BDCs) and Closed-End Funds (CEFs) as alternatives to traditional stocks for generating higher dividend income. While BDCs offer 90% income distribution requirements, they carry risks from lending to smaller companies. CEFs, particularly equity-focused ones, provide an attractive combination of ~8% average dividends with growth potential, with 97.7% of tracked CEFs profitable over the past decade and trading at a 5.3% discount to net asset value.

GOOG - Mentioned in context of YouTube TV dispute with Disney, no direct performance assessment
OBDC - Despite offering an 11.7% yield, OBDC has dropped 9% in 2025 even with dividends included, indicating poor total return performance and underperformance relative to alternatives.

#BDCs #CEFs #dividend income #private credit #equity funds #high yield #portfolio diversification

What Will Drive Starbucks (SBUX) Stock in 2026? 3 Important Factors Investors Must Watch.

The Motley Fool • Neil Patel

What Will Drive Starbucks (SBUX) Stock in 2026? 3 Important Factors Investors Must Watch.

12/25/2025 03:32 AM • Starbucks is undergoing a turnaround under CEO Brian Niccol with the 'Back to Starbucks' initiative focused on improving in-store experience and customer engagement. The company showed signs of recovery with 1% same-store sales growth in Q4 fiscal 2025, ending a six-quarter decline. Key factors to watch in 2026 include foot traffic improvement, brand strength maintenance, and expansion in China through a new joint venture selling a 60% stake in Chinese operations to a private equity firm, aiming to grow from 8,000 to 20,000 stores.

SBUX - The company is showing early signs of recovery with positive same-store sales growth after six quarters of decline, implementing a strategic turnaround plan, and pursuing significant growth opportunities in China through a major joint venture deal expected to expand its footprint substantially.

#turnaround strategy #same-store sales growth #customer engagement #China expansion #joint venture #brand strength #foot traffic #rewards program

2025 Rewind: Coinbase Makes S&P 500 Debut as Crypto Goes Mainstream

Investing.com • Hassan Shittu

2025 Rewind: Coinbase Makes S&P 500 Debut as Crypto Goes Mainstream

12/25/2025 01:35 AM • Coinbase made history in May 2025 by becoming the first cryptocurrency-native company to join the S&P 500 index. Despite not surpassing Charles Schwab in market value as some predicted, Coinbase demonstrated strong growth with 58.87% year-over-year revenue increase and expanded beyond crypto trading by launching stock trading and prediction markets in December 2025. The company holds over 80% of U.S. BTC and ETH ETF custodial assets and benefits from regulatory tailwinds under the pro-crypto Trump administration.

COIN - Coinbase achieved historic S&P 500 inclusion, demonstrated strong revenue growth (58.87% YoY), expanded into stock trading and prediction markets, holds dominant custodial position (80% of U.S. BTC/ETH ETF assets), and benefits from pro-crypto regulatory environment. Stock performance recovered from 2022-2023 volatility.

#S&P 500 inclusion #cryptocurrency mainstream adoption #crypto exchange #institutional participation #Bitcoin ETFs #stock trading expansion #regulatory tailwinds

Nvidia: $187 AI Core Stock, not Priced Like a Bubble

Investing.com • Itai Smidt

Nvidia: $187 AI Core Stock, not Priced Like a Bubble

12/25/2025 01:35 AM • Nvidia trades at $187 with a forward P/E of 24-40x while growing revenue and EPS at 40-60% annually. Despite a $4.5T valuation, the stock is not overpriced relative to fundamentals compared to other mega-caps. The company benefits from structural AI infrastructure demand, strong ecosystem moat via CUDA, and expanding margins. Key risks include geopolitical restrictions on chip exports to China, customer concentration (61% from four hyperscalers), and power grid constraints. The analyst rates Nvidia as a long-term Buy with a 2026 target around $340.7, acknowledging potential 30-40% drawdowns.

NVDA - Strong fundamentals with 40-60% revenue/EPS growth, 73.6% gross margins, expanding operating leverage, and a defensible CUDA moat. Forward P/E of 24-40x is reasonable relative to growth rates and comparable to S&P 500 despite superior metrics. Long-term Buy rating with $340.7 target implies 50-90% upside, though risks from geopolitical restrictions and customer concentration are acknowledged.

#AI infrastructure #data center #Blackwell architecture #CUDA ecosystem #chip exports #customer concentration #valuation #geopolitical risk

Investing.com • Dave Kovaleski

Will 2025 End With a Santa Claus Rally?

12/25/2025 01:34 AM • As 2025 approaches its end, markets are trending higher with the S&P 500 reaching an all-time high of 6,920 on Christmas Eve. The article examines the 'Santa Claus rally' concept—a seven-day period around year-end that historically shows positive returns 78% of the time with an average return of 1.3%. While recent momentum suggests favorable conditions for a positive rally, experts caution that seasonal trends are not guarantees and past performance doesn't predict future results.

ONEQ - The Nasdaq is ticking higher on Christmas Eve near all-time highs, indicating positive market momentum alongside the S&P 500.

#Santa Claus rally #S&P 500 #year-end market performance #seasonal trading patterns #market momentum #holiday trading

Rivian Stock Popped 15% Thursday, but There Could Be Room to Run

The Motley Fool • Daniel Miller

Rivian Stock Popped 15% Thursday, but There Could Be Room to Run

12/24/2025 07:33 PM • Rivian received a stock price boost and analyst upgrade to 'buy' with a $25 price target (up from $14) as the company prepares to launch its R2 vehicle in 2026. However, the EV market faces headwinds from the Trump administration's reduced EV support, tariffs, and elimination of the $7,500 federal tax credit. While Rivian has made progress on cost reduction and margins, the company continues to burn cash and faces intense competition in a struggling EV market.

RIVN - Mixed outlook: positive near-term catalyst with R2 launch and analyst upgrade to $25 target, but significant headwinds from policy changes, ongoing cash burn, lack of profitability, and weak EV market demand. Article suggests watching from sidelines rather than investing.

#Rivian R2 launch #EV market headwinds #analyst upgrade #federal tax credit elimination #automotive tariffs #gross margin improvement #EV demand weakness

Huntsman Stock Is Down 45% This Past Year, but One Fund Is Doubling Down With a $10 Million Bet

The Motley Fool • Jonathan Ponciano

Huntsman Stock Is Down 45% This Past Year, but One Fund Is Doubling Down With a $10 Million Bet

12/24/2025 06:37 PM • First Wilshire Securities Management increased its stake in Huntsman Corporation by purchasing 431,403 additional shares in Q3, bringing its total holding to 1.13 million shares worth $10.13 million. Despite Huntsman's stock declining 45% over the past year, the fund is betting on the company's strong cash flow generation and balance sheet durability in a cyclical chemicals industry, with management executing restructuring programs targeting $100+ million in savings.

WFCpZ - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
HUN - Stock is down 45% year-over-year with GAAP net losses, indicating significant near-term weakness. However, the company generates strong operating cash flow ($200M in Q3) and free cash flow ($157M in Q3) despite losses, maintains solid liquidity ($1.4B), and is executing cost-reduction programs. The fund's increased investment suggests confidence in long-term value based on cash generation and balance sheet strength rather than near-term earnings recovery.

#Huntsman Corporation #First Wilshire Securities Management #chemicals sector #cash flow #balance sheet #dividend reset #cyclical industry #specialty chemicals

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

The Motley Fool • Eric Volkman

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

12/24/2025 06:31 PM • Travere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmental glomerulosclerosis (FSGS), with an FDA decision expected by January 13, 2026.

TVTX - Stock gained 13.91% on positive analyst coverage highlighting blockbuster drug potential and takeover candidacy. FDA approval signals for Filspari in a new indication (FSGS) are encouraging, with decision expected January 13, 2026. The drug already has approval for treating IgAN since early 2024.

#Travere Therapeutics #Filspari #FDA approval #kidney disorder #FSGS #biotech #analyst upgrade #stock surge

Anfield Energy Amends Previously Announced Private Placement: US$6,000,000 Non-Brokered LIFE Offering of Common Shares and Concurrent US$4,000,000 Non-Brokered Private Placement of Subscription Receipts

GlobeNewswire Inc. • Anfield Energy Inc.

Anfield Energy Amends Previously Announced Private Placement: US$6,000,000 Non-Brokered LIFE Offering of Common Shares and Concurrent US$4,000,000 Non-Brokered Private Placement of Subscription Receipts

12/24/2025 04:56 PM • Anfield Energy announced amendments to its non-brokered private placement, consisting of up to 1.35M common shares at US$4.46 per share (US$6M gross proceeds) under the Listed Issuer Financing Exemption, plus a concurrent US$4M offering of subscription receipts to Uranium Energy Corp. The total offering is expected to reach US$10M, with proceeds allocated to capital commitments for the West Slope Project, Velvet-Wood Project, Slick Rock Project, and Shootaring Canyon Mill. The offering requires TSXV and NASDAQ approvals, as well as disinterested shareholder approval of Uranium Energy as a control person.

WFCpY - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
UEC - Uranium Energy's commitment to invest up to US$4M in subscription receipts and potential control position in Anfield indicates strategic interest in the uranium sector and confidence in Anfield's projects and management.

#private placement #LIFE offering #subscription receipts #capital financing #uranium development #shareholder approval #control person

The Motley Fool • Joe Tenebruso

Why Dynavax Stock Soared Today

12/24/2025 03:35 PM • Dynavax Technologies stock surged 38.19% after French pharmaceutical giant Sanofi announced an all-cash tender offer to acquire the biotech company for $15.50 per share, valuing it at approximately $2.2 billion. The deal represents a 39% premium to Dynavax's previous closing price and combines Dynavax's hepatitis B and shingles vaccines with Sanofi's global distribution network and development expertise.

WFCpL - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
DVAX - Stock soared 38.19% following announcement of acquisition by Sanofi at a 39% premium to previous closing price, providing shareholders with significant value and certainty of exit.

#acquisition #tender offer #vaccine #hepatitis B #shingles #biotech #merger

Video Presentation Explores What Altucher Calls “The Convergence of the Century”

GlobeNewswire Inc. • James Altucher

Video Presentation Explores What Altucher Calls “The Convergence of the Century”

12/24/2025 02:44 PM • Technology analyst James Altucher released a video presentation arguing that the convergence of artificial intelligence and quantum computing represents a historic inflection point comparable to past technological breakthroughs. He cites Bank of America's projection of $111 trillion in potential new wealth and highlights growing momentum through increased patent filings, major tech firm investments, and real-world testing in healthcare, logistics, and finance sectors.

WFCpD - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
BAC - Bank of America is cited as a credible institutional source projecting $111 trillion in wealth creation from AI-quantum convergence, positioning the bank as a research authority on this technological shift and implicitly supporting the investment thesis.

#artificial intelligence #quantum computing #technological convergence #market inflection point #wealth creation #emerging technologies #patent filings #investment trends

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Coupang, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – CPNG

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Coupang, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – CPNG

12/24/2025 02:44 PM • Rosen Law Firm has filed a class action lawsuit against Coupang, Inc. on behalf of investors who purchased securities between August 6, 2025 and December 16, 2025. The lawsuit alleges that Coupang failed to disclose a significant data breach caused by inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for nearly six months. The firm claims defendants made false and misleading statements and failed to file required SEC reports regarding the breach, causing investor damages when the true details became public.

WFCpC - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
CPNG - The company is the subject of a securities class action lawsuit alleging inadequate cybersecurity protocols, unauthorized data access by a former employee, failure to properly disclose the breach to the SEC, and making false/misleading statements to investors. These allegations of fraud and regulatory non-compliance represent significant legal and reputational risks.

#class action lawsuit #data breach #cybersecurity #securities fraud #SEC disclosure #investor damages #lead plaintiff deadline

Mondelēz Global LLC Conducts Voluntary Recall of 2 SKUs of CHIPS AHOY! Baked Bites Brookie in the US

GlobeNewswire Inc. • Na

Mondelēz Global LLC Conducts Voluntary Recall of 2 SKUs of CHIPS AHOY! Baked Bites Brookie in the US

12/24/2025 02:00 PM • Mondelēz Global LLC issued a voluntary recall of CHIPS AHOY! Baked Bites Brookie products due to an incorrect mixing process that created corn starch clumps, posing a potential choking hazard for young children and elderly consumers. The recall is limited to specific Best When Used By dates and a limited number of retail stores. No injuries or illnesses have been reported.

GSpD - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
MDLZ - The voluntary recall of a consumer product indicates a manufacturing quality control issue. While the company is being proactive and no injuries have been reported, recalls can damage brand reputation and consumer trust, and may result in financial costs related to the recall process and potential legal liability.

#product recall #choking hazard #CHIPS AHOY! #corn starch clumps #food safety #manufacturing defect

GBPPromote Launches Google Reviews Management Software

GlobeNewswire Inc. • Gbppromote

GBPPromote Launches Google Reviews Management Software

12/24/2025 01:49 PM • GBPPromote has launched a new Google Reviews Management Software designed to help businesses manage online reviews, protect their reputation, and build customer trust. The platform features a unified dashboard, automated review requests, sentiment analysis, and bad review detection. With over 5,000 agencies already onboarded, GBPPromote is expanding its offerings with upcoming tools for Google Business Profile management, local citation tracking, and local rank monitoring.

WFC - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
GOOG - Google is mentioned primarily as the platform whose reviews GBPPromote manages. While the article references Google's review moderation efforts (170M+ reviews removed in 2023, 240M+ in 2024), this is presented as factual context rather than positive or negative commentary on Google's business performance.

#Google Reviews Management #online reputation #review automation #local SEO #Google Business Profile #customer trust #review generation #sentiment analysis #multi-location management #fake review detection

What's the Best-Performing S&P 500 Stock in 2025?

The Motley Fool • Matthew Benjamin

What's the Best-Performing S&P 500 Stock in 2025?

12/24/2025 01:32 PM • Sandisk (SNDK) is the best-performing S&P 500 stock in 2025, with shares up 570% since its February IPO at $38.50, now trading around $250. The memory and storage device manufacturer benefited from a global chip shortage driven by AI and consumer electronics demand, posting strong Q1 results with 21% revenue growth to $2.3B and earnings more than double analyst expectations.

WFCpA - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
SNDK - Exceptional 570% stock price gain in 2025, strong fiscal Q1 earnings beat (earnings 2x+ consensus, revenue 9% above expectations), benefits from global memory chip shortage driven by AI competition, and positive market reception with 15% pop after earnings announcement.

#Sandisk #S&P 500 #best-performing stock #NAND flash memory #chip shortage #AI demand #IPO #earnings beat

Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

Benzinga • Vandana Singh

Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

12/24/2025 12:31 PM • The FDA approved Novo Nordisk's Wegovy pill, the first oral GLP-1 weight-loss medication, which demonstrated 16.6% mean weight loss in trials. As GLP-1 adoption accelerates, major food and restaurant companies are rapidly adjusting their menus and products toward higher-protein, smaller-portion offerings to cater to changing consumer eating habits, with companies like ConAgra, Chipotle, and Danone already seeing strong performance in these new product lines.

GSpC - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
NVO - FDA approval of Wegovy pill as first oral GLP-1 therapy with strong clinical trial results (16.6% mean weight loss) and expected U.S. launch in early January 2026 represents significant market expansion opportunity.

#GLP-1 medications #Wegovy pill approval #weight loss drugs #menu innovation #high-protein products #portion control #consumer eating habits

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

12/24/2025 11:50 AM • Rezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, a lead drug candidate for congenital hyperinsulinism. The study failed to meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events versus placebo. Securities law firm Faruqi & Faruqi is investigating potential claims against the company on behalf of affected investors.

RZLT - The company's lead drug candidate failed to meet primary and secondary endpoints in Phase 3 trials, resulting in sharp stock decline and triggering securities litigation investigation. This represents a significant setback for the company's pipeline and investor confidence.

#clinical trial failure #Phase 3 trial #stock decline #securities litigation #congenital hyperinsulinism #ersodetug #investor losses

Notice of Investigation of VRNS: Kessler Topaz Meltzer & Check, LLP Encourages Varonis Systems, Inc. (NASDAQ: VRNS) Investors with Significant Losses to Contact the Firm

GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

Notice of Investigation of VRNS: Kessler Topaz Meltzer & Check, LLP Encourages Varonis Systems, Inc. (NASDAQ: VRNS) Investors with Significant Losses to Contact the Firm

12/24/2025 11:50 AM • Law firm Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Varonis Systems, Inc. after the company reported Q3 2025 results showing a 63.9% decline in term license subscription revenues and reduced full-year ARR guidance. The stock fell 48.67% on October 29, 2025, following disclosure of sales process issues and lower renewal rates in the on-premises subscription business.

VRNS - Company reported significant revenue miss with 63.9% decline in term license subscription revenues, reduced full-year ARR guidance, disclosed sales process issues, and experienced a 48.67% stock price decline. Federal securities law violations are being investigated by a major law firm.

#securities fraud investigation #Varonis Systems #revenue miss #subscription revenue decline #stock price drop #class action lawsuit #ARR guidance reduction

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sprouts

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sprouts

12/24/2025 11:39 AM • A securities class action has been filed against Sprouts Farmers Market for allegedly making false and misleading statements about the company's growth potential. On October 29, 2025, Sprouts reported disappointing third quarter results with comparable store sales declining 4.3% and reduced full-year guidance from 7.5%-9% to 7%. The stock fell $22.64 per share following the announcement. Investors who purchased securities between June 4 and October 29, 2025 have until January 26, 2026 to seek lead plaintiff status.

SFM - The company is facing a federal securities class action alleging false and misleading statements about growth potential. Q3 results showed a 4.3% decline in comparable store sales, significantly below projections, and full-year guidance was reduced. The stock price fell sharply ($22.64 per share) following the disappointing earnings announcement.

#securities litigation #class action #false statements #comparable store sales decline #guidance reduction #stock price decline #lead plaintiff deadline

NJDCY INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nidec

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

NJDCY INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nidec

12/24/2025 11:36 AM • Nidec Corporation faces a securities investigation following multiple disclosures of improper accounting practices discovered by a third-party committee. The company revealed suspected inappropriate accounting involving management, customs value misreporting, and deficiencies in internal controls. These revelations triggered significant stock price declines across four separate announcements between September and October 2025, with the Tokyo Stock Exchange placing the company under a Special Security alert.

GS - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
NJDCY - Multiple accounting fraud allegations, management involvement in improper practices, audit disclaimer of opinion, withdrawal of financial forecasts, suspension of dividend payments, and Tokyo Stock Exchange Special Security alert designation. Stock declined approximately 68% from initial disclosure through final alert announcement.

#improper accounting #securities litigation #internal investigation #stock price decline #Tokyo Stock Exchange #internal controls #audit disclaimer

Why Is Dermata Therapeutics Stock Surging Wednesday?

Benzinga • Lekha Gupta

Why Is Dermata Therapeutics Stock Surging Wednesday?

12/24/2025 11:32 AM • Dermata Therapeutics (NASDAQ: DRMA) stock surged 20.10% on Wednesday following the announcement of a $12.4 million private placement offering. The company will issue 2,022,062 common shares and warrants priced at $2.04 per share, with expected gross proceeds of $4.1 million. If warrants are fully exercised, the company could raise an additional $8.3 million. Net proceeds will fund consumer research, OTC acne kit launch activities, and working capital. The stock is trading near its 52-week low of $1.96.

GSpA - Mentioned as a joint book-running manager for the offering, performing a standard financial service role
DRMA - Stock surged 20.10% on announcement of $12.4 million private placement offering with insider participation, providing capital for product launch and operations. However, the positive sentiment is tempered by the stock trading near its 52-week low, indicating underlying weakness despite the near-term rally.

#private placement offering #warrant exercise #capital raise #OTC acne kit #stock surge

HD Investors Have Opportunity to Join The Home Depot, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

HD Investors Have Opportunity to Join The Home Depot, Inc. Fraud Investigation with the Schall Law Firm

12/24/2025 11:00 AM • The Schall Law Firm is investigating The Home Depot for potential securities violations following the company's Q3 2025 earnings announcement on November 18, 2025. Home Depot missed sales forecasts, attributing the shortfall to lack of storms and consumer uncertainty in housing. The stock fell over 6% on the news. The firm is seeking shareholders who suffered losses to participate in the investigation.

KMX - Only briefly mentioned with no substantive details about performance
HD - The company missed sales forecasts, experienced a 6% stock price decline, and is now subject to a fraud investigation by a securities litigation firm, indicating serious concerns about potential misstatements or disclosure failures to investors.

#fraud investigation #securities violation #earnings miss #shareholder lawsuit #Q3 2025 results